Everything below concerns melanocortin receptor. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-03-09. Where a claim depends on a specific study, the study is described rather than over-claimed.
Melanotan II binds several melanocortin receptor subtypes rather than a single target. MC1R on melanocytes drives melanin synthesis, while MC3R and MC4R participate in energy balance, appetite, and sexual response pathways. This lack of selectivity explains why reported effects extend beyond skin darkening. Substitutions at positions four and seven, including norleucine and D-phenylalanine, increase potency and resistance to peptidases. Understanding which receptor mediates which effect remains an active area of investigation.
Published human data come mostly from small, short studies rather than large controlled trials. Reported outcomes include increased skin pigmentation and, in some reports, effects on appetite and libido, but sample sizes are small and follow-up is limited. Whether long-term use produces durable pigment changes or adverse effects is not established. Because products sold outside pharmacies are not standardized, the actual content of any given vial is often unknown. Independent testing of such material is uncommon.
Melanotan II is a synthetic cyclic heptapeptide analog derived from the core sequence of alpha-melanocyte-stimulating hormone. Researchers at the University of Arizona synthesized it during the 1980s while studying pigmentation and appetite signaling. The compound is not an approved medicine in any major jurisdiction and appears mainly in laboratory and research-chemical settings. Its structure incorporates a lactam bridge between side chains, which constrains the ring and slows enzymatic breakdown relative to the natural hormone.
Early published reports described melanotan-2 as a tanning agent without sun protection, which means darkening is not the same as protection against ultraviolet radiation. Later studies explored the peptide in erectile dysfunction, hemorrhagic shock, and some skin conditions. No regulator in the United States or Europe has approved it for clinical use. Many products labelled melanotan-2 are sold without approval and their identity and purity are unverified. Its long-term safety in humans remains an open question.
Melanotan-2, also written Melanotan II, is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, and the lactam bridge between the aspartate and lysine side chains constrains the peptide into a ring. This structural change increases receptor affinity and metabolic stability relative to the native hormone. The compound was created in the 1980s as a research tool for studying pigmentation biology.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Analog of alpha-melanocyte-stimulating hormone |
| Primary receptor family | Melanocortin receptors MC1R through MC5R | Binding is not subtype-selective |
| Development period | 1980s | Synthesized during pigmentation and appetite research |
| Regulatory status | Not an approved medicine | No major regulator has authorized human use |
| Related compound | Afamelanotide | Linear analog studied for photoprotection |
Receptor binding at MC1R on melanocytes raises intracellular cyclic AMP and increases expression of tyrosinase and related enzymes. The downstream result is greater synthesis of eumelanin, the dark pigment, without ultraviolet exposure acting as the trigger. The compound is not selective, however, and also engages MC3R, MC4R and MC5R, which are expressed in the central nervous system and elsewhere. That lack of selectivity is the explanation usually offered for effects reported outside pigmentation, including appetite suppression and nausea. Selectivity remains a central theme in comparative studies of related peptides.
Human data remain limited and mostly short-term. Reports describe small trials and observational accounts rather than large controlled studies, so questions about dose-response relationships and long-term effects on melanocytes stay open. Whether repeated exposure alters naevus behaviour is not settled in the published record. Researchers also note that self-administered use outside clinical settings makes actual exposure difficult to quantify. Statements about efficacy and safety should therefore be read as preliminary rather than established.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, the naturally occurring peptide involved in pigmentation signalling. Its sequence is conventionally written as Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, with a lactam bridge joining the aspartate side chain to the lysine side chain. The empirical formula is C50H69N15O9 and the monoisotopic mass lies near 1023.5 daltons. N-terminal acetylation and the D-configured phenylalanine both increase resistance to enzymatic breakdown compared with the parent hormone.
Pharmacologically, melanotan-2 behaves as a non-selective agonist across the melanocortin receptor family. Binding at MC1R on dermal melanocytes promotes eumelanin synthesis, which underlies the tanning response described in early human work. Activity at the centrally expressed MC4R receptor is associated with reported effects on appetite and erectile function. Because the peptide does not discriminate strongly among receptor subtypes, attributing any single observed effect to one receptor pathway is generally not possible without selective antagonists or receptor knockout models.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence incorporates a lactam bridge that constrains the peptide into a ring, which increases resistance to enzymatic breakdown relative to the natural hormone. Researchers at the University of Arizona synthesised the compound in the late 1980s and early 1990s while studying pigmentation pathways. It has never received marketing approval from any national medicines regulator. In the scientific literature it is usually described as a laboratory research reagent rather than a therapeutic product.
The peptide acts as a non-selective agonist at melanocortin receptors, showing affinity for MC1R, MC3R, MC4R and MC5R. Activation of MC1R on melanocytes drives the conversion of tyrosine into melanin and shifts production toward the darker eumelanin form. MC4R signalling in the central nervous system is linked to appetite and energy balance, which helps explain why reduced food intake appeared in early human studies. Effects on MC4R and on vascular tone also account for the erectile responses recorded as unexpected findings in those same trials.
Melanotan-2 is frequently confused with afamelanotide, a linear analogue authorised in the European Union for erythropoietic protoporphyria. The two compounds differ in chain length, ring structure and receptor selectivity, so findings for one cannot be transferred directly to the other. Published controlled human data on melanotan-2 remain sparse, and much of what circulates online derives from small studies or unpublished reports. Questions about effect size, dose-response behaviour and long-term safety therefore remain unresolved.
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.
In the case of children and young people, especially if they are socially disadvantaged, research suggests that it is important that healthcare providers listen to and discuss their feelings and life situation to help them engage with diabetes services and self-management. To this end, treatment programs such as the Cognitive Behavioural Therapy - Adherence and Depression program (CBT-AD) have been developed to target the psychological mechanisms underpinning adherence.
Tholos de Montelirio is an archaeological site in Seville Province, Spain, at Valencina de la Concepción. It is a megalithic construction dated to 3,000–2,800 BC. The site was discovered in 1868, but has been abandoned for decades. Its excavation was resumed in 1980 due to the urban growth of Seville. Tholos de Montelirio is closed to the general public, but its objects can be viewed in the Archeological Museum of Seville.
== Enabling environment == According to the McKinsey Industry Digitization Index, the agricultural sector is the slowest adopter of digital technologies in the United States. Farm-level adoption of digital agriculture varies within and between countries, and uptake differs by technology. Some characterize precision agriculture uptake as rather slow. In the United States in 2010-2012, precision agriculture technologies were used on 30-50% of corn and soybean acreage. Others point out that uptake varies by technology; farmer use of GNSS guidance has grown rapidly, but variable-rate technology adoption rarely exceeds 20% of farms. Furthermore, digital agriculture is not limited to on-farm precision tools, and these innovations typically require less upfront investment. Growing access to ICTs in agriculture and a booming e-commerce market all bode well for increased adoption of digital agriculture downstream of the farm. Individual farmers' perceptions about usefulness, ease of use, and cost-effectiveness impact the spread of digital agriculture. In addition, a number of broader factors enable the spread of digital agriculture, including:
== SB == Sb – (s) Antimony (Latin Stibium) SbA - Stibarsen, an alloy of antimony and arsenic SB (i) Sexy Bitch Sexy Bastard Sexy Boy (disambiguation) (s) Solomon Islands (ISO 3166 digram) (i) Special Warfare Boat Operator SBA (i) Santa Barbara Airport Simulation-Based Acquisition Small Business Administration Sovereign Base Area Student bar association SBB – (i) German for the Swiss Federal Railways SBC (i) Sensotronic Brake Control Single-Board Computer Southern Baptist Convention Sun Belt Conference (US college sports) SBCCOM – (p) U.S. Army Soldier and Biological Chemical Command (disbanded 2003) SBCS – (i) Single-Byte Character Set SBCT – (i) Stryker Brigade Combat Team SBD (s) Solomon Islands dollar (ISO 4217 currency code) Silent But Deadly SBP (i) Samahang Basketbol ng Pilipinas (Filipino, "Basketball Federation of the Philippines") U.S. School Breakfast Program Society of Business Practitioners State Bank of Pakistan SBS (i) Special Boat Service Special Broadcasting Service Seoul Broadcasting System SBW (i) Sonny Bill Williams (New Zealand dual-code rugby player)
Plasma transfusion is especially prone to causing TACO because large volumes are usually required to give any therapeutic benefit. Transfusion-associated graft versus host disease frequently occurs in immunodeficient patients where recipient's body failed to eliminate donor's T cells. Instead, donor's T cells attack the recipient's cells. It occurs one week after transfusion. Fever, rash, diarrhoea are often associated with this type of transfusion reaction. Mortality rate is high, with 89.7% of the patients dead after 24 days. Immunosuppressive treatment is the most common way of treatment. Irradiation and leukoreduction of blood products is necessary for high risk patients to prevent T cells from attacking recipient cells.
Sources: en.wikipedia.org
== External links == Lesch-Nyhan Syndrome at NIH's Office of Rare Diseases GeneReview/NIH/UW entry on Lesch–Nyhan syndrome National Institute of Child Health and Human Development (NICHD) Love Never Sinks • Lesch Nyhan• Patient Advocacy Group
=== Certification of 2020 presidential election === On January 6, 2021, Wittman was one of the 147 Republican members of the U.S. Congress who objected to certifying the 2020 presidential election. He voted against certifying Pennsylvania's electors after a day of violence as the U.S. Capitol was breached by Trump supporters who disrupted proceedings, despite no clear evidence of widespread voter fraud.
Dichloroacetic acid (DCA), sometimes called bichloroacetic acid (BCA), is the organic compound with formula CHCl2CO2H. It is an analogue of acetic acid, in which 2 of the 3 hydrogen atoms of the methyl group have been replaced by chlorine atoms. Like the other chloroacetic acids, it has various practical applications. The salts and esters of dichloroacetic acid are called dichloroacetates.
== Overdose == Only a single case of death due to mescaline, as peyote, has been described, and was likely due to asphyxiation by vomit rather than overdose or toxicity. However, there is also a case report of death due to jumping off a cliff while on a high dose of mescaline. In terms of extrapolated human lethal dose based on animal studies, the lethal dose of mescaline relative to a typical recreational dose has been estimated to be 24-fold or around 8,400 mg. However, mescaline has reportedly been taken by humans at doses of up to 8,000 mg without apparent toxic reactions. On the other hand, there is one unverified reported case of death due to a dose of 15,000 mg intravenously, which would equate to about 150 to 200 mg/kg. The median lethal dose (LD50) of mescaline has been determined in various animal species, with the values including 212 to 315 mg/kg i.p. in mice, 132 to 410 mg/kg i.p. in rats, 328 mg/kg i.p. in guinea pigs, 54 mg/kg in dogs, and 130 mg/kg i.v. in rhesus macaques, among others. It has been said that it would be difficult to take enough mescaline to cause death in humans. No deaths due to peyote use have been reported aside from the asphyxiation case. The highest dose of peyote known to have been taken is 90 dried buttons.
Sources: en.wikipedia.org
== Related compounds == Numerous other compounds similar to levonantradol were also developed at the same time, including CP 42,096, CP 47,497, CP 55,940 and CP 55,244. The desacetyl derivative of levonantradol (DALN or CP 54,939) and its N-methyl derivative, as well as the tetracyclic analogue all have similar activity to levonantradol itself.
16 August – A university reports the release of 'Quad-SDK' which may be the first open source full-stack software for large agile four-legged robots, compatible with the ROS. 17 August A report by Global Forest Watch, using new data, concludes that the amount of tree cover being burned has nearly doubled in the past 20 years. The Nadir crater, likely the result of a second, smaller asteroid that struck around the same time as the Chicxulub impact, is identified and described by researchers. Geologists warn that the world is "woefully underprepared" for a massive volcanic eruption. They estimate a one-in-six chance of a magnitude seven explosion in the next one hundred years. Researchers report the development of floating artificial leaves for light-driven hydrogen and syngas fuel production. The lightweight, flexible devices are scalable and can float on water similar to lotus leaves.
In polymer chemistry, step-growth polymerization is a type of polymerization mechanism in which bi-functional or multifunctional monomers react to form first dimers, then trimers, longer oligomers, and eventually long-chain polymers. Many naturally occurring and some synthetic polymers are produced by step-growth polymerization, such as polyesters, polyamides, polyurethanes, etc. Due to the nature of the polymerization mechanism, a high extent of reaction is required to achieve high molecular weight. The easiest way to visualize the mechanism of a step-growth polymerization is a group of people reaching out to hold their hands to form a human chain—each person has two hands (reactive sites). There also is the possibility to have more than two reactive sites on a monomer: In this case branched-polymer production takes place. IUPAC has deprecated the term step-growth polymerization, and recommends use of the terms polyaddition (when the propagation steps are addition reactions and molecules are not evolved during these steps) and polycondensation (when the propagation steps are condensation reactions and molecules are evolved during these steps).
Sources: en.wikipedia.org
No regulator in a major market has approved it for human use. It appears in research settings and in products marketed outside pharmacy channels. Legal status for personal possession varies by country.
Afamelanotide is a linear analog that has received approval in some jurisdictions for a specific photoprotection indication. Melanotan II is cyclic and less selective across melanocortin receptors. The two are related but are not interchangeable in regulatory or clinical terms.
A compound that activates several receptor subtypes may produce effects beyond pigmentation. Selectivity influences which tissues respond and shapes the side-effect profile described in reports. Designing subtype-selective analogs is a stated goal of melanocortin research.
No. It is a laboratory-made peptide, while the natural hormone is alpha-melanocyte-stimulating hormone, a longer peptide produced by the pituitary gland and by skin cells. Melanotan-2 mimics only a short active region of that hormone and contains non-natural residues such as D-phenylalanine.